TCDA - Tricida stock rises 3% aftermarket on review of strategic alternatives
- Tricida ( NASDAQ: TCDA ) stock rose 3.2% postmarket on Wednesday after the drugmaker said it will initiate a review of strategic alternatives to maximize shareholder value.
- The strategic review may include a sale of the company and/or its assets.
- Tricida ( TCDA ) is also evaluating plans to reduce operating expenses, which it expects to initiate this month.
- Shares of Tricida ( TCDA ) dropped ~97% YTD.
- The company last week said its phase 3 trial for kidney disease candidate veverimer did not meet the main goal, sending its shares crashing ~94% .
For further details see:
Tricida stock rises 3% aftermarket on review of strategic alternatives